Tetrabenazine

Bibliography

• Lende N. Psychosedative effects of tetrabenazine (RO 1-9569) on hyperactive and disturbed mentally retarded patients. Dis Nerv Syst 1960;21(Suppl 3):118-19
   PubMedGoogle Scholar
• Pakkenberg H. The effect of tetrabenazine in some hyperkinetic syndromes. Acta Neurol Scand 1968;44:391-3
   PubMedGoogle Scholar
• Mehvar R, Jamali F, Watson MW, Pharmacokinetics of tetrabenazine and its major metabolite in man and rat. Bioavailability and dose dependency studies. Drug Metab Dispos 1987;15:250-5
   PubMedGoogle Scholar
• Roberts MS, McLean S, Millingen KS, The pharmacokinetics of tetrabenazine and its hydroxy metabolite in patients treated for involuntary movement disorders. Eur J Clin Pharmacol 1986;29:703-8
   PubMed Web of Science ®Google Scholar
• Roberts MS, Watson HM, McLean S, Determination of therapeutic plasma concentrations of tetrabenazine and an active metabolite by high-performance liquid chromatography. J Chromatogr 1981;226:175-82
   PubMedGoogle Scholar
• Jankovic J. Tetrabenazine in the treatment of hyperkinetic movement disorders. Adv Neurol 1983;37:277-89
   PubMedGoogle Scholar
• Gonzalez AM, Walther D, Pazos A, Synaptic vesicular monoamine transporter expression: distribution and pharmacologic profile. Brain Res Mol Brain Res 1994;22:219-26
   PubMedGoogle Scholar
• Erickson JD, Schafer MK, Bonner TI, Distinct pharmacological properties and distribution in neurons and endocrine cells of two isoforms of the human vesicular monoamine transporter. Proc Natl Acad Sci USA 1996;93:5166-71
   PubMed Web of Science ®Google Scholar
• Quinn GP, Shore PA, Brodie BB. Biochemical and pharmacological studies of RO 1-9569 (tetrabenazine), a nonindole tranquilizing agent with reserpine-like effects. J Pharmacol Exp Ther 1959;127:103-9
   PubMed Web of Science ®Google Scholar
• Pettibone DJ, Totaro JA, Pflueger AB. Tetrabenazine-induced depletion of brain monoamines: characterization and interaction with selected antidepressants. Eur J Pharmacol 1984;102:425-30
   PubMed Web of Science ®Google Scholar
• Scherman D, Boschi G, Rips R, The regionalization of [3H]dihydrotetrabenazine binding sites in the mouse brain and its relationship to the distribution of monoamines and their metabolites. Brain Res 1986;370:176-81
   PubMedGoogle Scholar
• Pearson SJ, Reynolds GP. Depletion of monoamine transmitters by tetrabenazine in brain tissue in Huntington's disease. Neuropharmacology 1988;27:717-19
   PubMed Web of Science ®Google Scholar
• Login IS, Cronin MJ, MacLeod RM. Tetrabenazine has properties of a dopamine receptor antagonist. Ann Neurol 1982;12:257-62
   PubMed Web of Science ®Google Scholar
• Reches A, Burke RE, Kuhn CM, Tetrabenazine, an amine-depleting drug, also blocks dopamine receptors in rat brain. J Pharmacol Exp Ther 1983;225:515-21
   PubMed Web of Science ®Google Scholar
• Pletscher A, Brossi A, Gey K. Benzoquinolizine derivatives: a new class of monoamine decreasing drugs with psychotropic action. Int Rev Neurobiol 1962;4:275-306
   Web of Science ®Google Scholar
• Burke RE, Reches A, Traub MM, Tetrabenazine induces acute dystonic reactions. Ann Neurol 1985;17:200-2
   PubMedGoogle Scholar
• McLellan DL, Chalmers RJ, Johnson RH. A double-blind trial of tetrabenazine, thiopropazate, and placebo in patients with chorea. Lancet 1974;1:104-7
   PubMed Web of Science ®Google Scholar
• Tomlinson DR. The mode of action of tetrabenazine on peripheral noradrenergic nerves. Br J Pharmacol 1977;61:339-44
   PubMedGoogle Scholar
• Thibaut F, Faucheux BA, Marquez J, Regional distribution of monoamine vesicular uptake sites in the mesencephalon of control subjects and patients with Parkinson's disease: a postmortem study using tritiated tetrabenazine. Brain Res 1995;692:233-43
   PubMedGoogle Scholar
• Mehvar R, Jamali F. Concentration-effect relationships of tetrabenazine and dihydrotetrabenazine in the rat. J Pharm Sci 1987;76:461-5
   PubMedGoogle Scholar
• Tang TS, Chen X, Liu J, Dopaminergic signaling and striatal neurodegeneration in Huntington's disease. J Neurosci 2007;27:7899-910
   PubMedGoogle Scholar
• Satou T, Anderson AJ, Itoh T, Repetitive administration of tetrabenazine induces irreversible changes in locomotion and morphology of the substantia nigra in rats. Exp Toxicol Pathol 2001;53:303-8
   PubMedGoogle Scholar
• Roze E, Saudou F, Caboche J. Pathophysiology of Huntington's disease: from huntingtin functions to potential treatments. Curr Opin Neurol 2008;21:497-503
   PubMed Web of Science ®Google Scholar
• Phillips W, Shannon KM, Barker RA. The current clinical management of Huntington's disease. Mov Disord 2008;23:1491-504
   PubMed Web of Science ®Google Scholar
• Leonard DP, Kidson MA, Brown JG, A double blind trial of lithium carbonate and haloperidol in Huntington's chorea. Aust NZ J Psychiatry 1975;9:115-18
   PubMed Web of Science ®Google Scholar
• Caine ED, Polinsky RJ, Kartzinel R, The trial use of clozapine for abnormal involuntary movement disorders. Am J Psychiatry 1979;136:317-20
   PubMed Web of Science ®Google Scholar
• Roos RA, Buruma OJ, Bruyn GW, Tiapride in the treatment of Huntington's chorea. Acta Neurol Scand 1982;65:45-50
   PubMed Web of Science ®Google Scholar
• Quinn N, Marsden CD. A double blind trial of sulpiride in Huntington's disease and tardive dyskinesia. J Neurol Neurosurg Psychiatry 1984;47:844-7
   PubMed Web of Science ®Google Scholar
• Deroover J, Baro F, Bourguignon RP, Tiapride versus placebo: a double-blind comparative study in the management of Huntington's chorea. Curr Med Res Opin 1984;9:329-38
   PubMed Web of Science ®Google Scholar
• van Vugt JP, Siesling S, Vergeer M, Clozapine versus placebo in Huntington's disease: a double blind randomised comparative study. J Neurol Neurosurg Psychiatry 1997;63:35-9
   PubMed Web of Science ®Google Scholar
• Berardelli A, Noth J, Thompson PD, Pathophysiology of chorea and bradykinesia in Huntington's disease. Mov Disord 1999;14:398-403
   PubMedGoogle Scholar
• Kingston D. Tetrabenazine for involuntary movement disorders. Med J Aust 1979;1:628-30
   PubMed Web of Science ®Google Scholar
• Jankovic J, Orman J. Tetrabenazine therapy of dystonia, chorea, tics, and other dyskinesias. Neurology 1988;38:391-4
   PubMed Web of Science ®Google Scholar
• Asher SW, Aminoff MJ. Tetrabenazine and movement disorders. Neurology 1981;31:1051-4
   PubMed Web of Science ®Google Scholar
• Ondo WG, Tintner R, Thomas M, Tetrabenazine treatment for Huntington's disease-associated chorea. Clin Neuropharmacol 2002;25:300-2
   PubMed Web of Science ®Google Scholar
• Huntington Study Group. Tetrabenazine as antichorea therapy in Huntington disease: a randomized controlled trial. Neurology 2006;66:366-72
   PubMed Web of Science ®Google Scholar
• Frank S, Ondo W, Fahn S, A study of chorea after tetrabenazine withdrawal in patients with Huntington disease. Clin Neuropharmacol 2008;31:127-33
   PubMed Web of Science ®Google Scholar
• Jankovic J, Beach J. Long-term effects of tetrabenazine in hyperkinetic movement disorders. Neurology 1997;48:358-62
   PubMed Web of Science ®Google Scholar
• Kenney C, Hunter C, Jankovic J. Long-term tolerability of tetrabenazine in the treatment of hyperkinetic movement disorders. Mov Disord 2007;22:193-7
   PubMed Web of Science ®Google Scholar
• Fasano A, Cadeddu F, Guidubaldi A, The long-term effect of tetrabenazine in the management of Huntington disease. Clin Neuropharmacol 2008;31:313-18
   PubMed Web of Science ®Google Scholar
• Mahant N, McCusker EA, Byth K, Huntington's disease: clinical correlates of disability and progression. Neurology 2003;61:1085-92
   PubMed Web of Science ®Google Scholar
• Pasricha PJ, Pehlivanov N, Sugumar A, Drug insight: from disturbed motility to disordered movement–a review of the clinical benefits and medicolegal risks of metoclopramide. Nat Clin Pract Gastroenterol Hepatol 2006;3:138-48
   PubMedGoogle Scholar
• Stacy M, Cardoso F, Jankovic J. Tardive stereotypy and other movement disorders in tardive dyskinesias. Neurology 1993;43:937-41
   PubMed Web of Science ®Google Scholar
• Halliday J, Farrington S, Macdonald S, Nithsdale Schizophrenia Surveys 23: movement disorders. 20-year review. Br J Psychiatry 2002;181:422-7
   PubMed Web of Science ®Google Scholar
• Kazamatsuri H, Chien C, Cole JO. Treatment of tardive dyskinesia. I. Clinical efficacy of a dopamine-depleting agent, tetrabenazine. Arch Gen Psychiatry 1972;27:95-9
   PubMed Web of Science ®Google Scholar
• Kazamatsuri H, Chien CP, Cole JO. Long-term treatment of tardive dyskinesia with haloperidol and tetrabenazine. Am J Psychiatry 1973;130:479-83
   PubMed Web of Science ®Google Scholar
• Ondo WG, Hanna PA, Jankovic J. Tetrabenazine treatment for tardive dyskinesia: assessment by randomized videotape protocol. Am J Psychiatry 1999;156:1279-81
   PubMed Web of Science ®Google Scholar
• Stacy M, Jankovic J. Tardive tremor. Mov Disord 1992;7:53-7
   PubMed Web of Science ®Google Scholar
• Storey E, Lloyd J. Tardive tremor. Mov Disord 1997;12:808-10
   PubMedGoogle Scholar
• Leckman JF. Tourette's syndrome. Lancet 2002;360:1577-86
   PubMed Web of Science ®Google Scholar
• Sweet RD, Bruun R, Shapiro E, Presynaptic catecholamine antagonists as treatment for Tourette syndrome. Effects of alpha methyl para tyrosine and tetrabenazine. Arch Gen Psychiatry 1974;31:857-61
   PubMed Web of Science ®Google Scholar
• Jankovic J, Glaze DG, Frost JD Jr. Effect of tetrabenazine on tics and sleep of Gilles de la Tourette's syndrome. Neurology 1984;34:688-92
   PubMed Web of Science ®Google Scholar
• Jankovic J, Rohaidy H. Motor, behavioral and pharmacologic findings in Tourette's syndrome. Can J Neurol Sci 1987;14:541-6
   PubMed Web of Science ®Google Scholar
• Paleacu D, Giladi N, Moore O, Tetrabenazine treatment in movement disorders. Clin Neuropharmacol 2004;27:230-3
   PubMed Web of Science ®Google Scholar
• Jankovic J. Treatment of hyperkinetic movement disorders with tetrabenazine: a double-blind crossover study. Ann Neurol 1982;11:41-7
   PubMed Web of Science ®Google Scholar
• Marsden CD, Harrison MJ. Idiopathic torsion dystonia (dystonia musculorum deformans). A review of forty-two patients. Brain 1974;97:793-810
   PubMed Web of Science ®Google Scholar
• Marsden CD, Marion MH, Quinn N. The treatment of severe dystonia in children and adults. J Neurol Neurosurg Psychiatry 1984;47:1166-73
   PubMedGoogle Scholar
• Mariotti P, Fasano A, Contarino MF, Management of status dystonicus: our experience and review of the literature. Mov Disord 2007;22:963-8
   PubMed Web of Science ®Google Scholar
• Scott BL. Evaluation and treatment of dystonia. South Med J 2000;93:746-51
   PubMedGoogle Scholar
• Hoehn MM, Cherington M. Spinal myoclonus. Neurology 1977;27:942-6
   PubMedGoogle Scholar
• Jankovic J, Pardo R. Segmental myoclonus. Clinical and pharmacologic study. Arch Neurol 1986;43:1025-31
   PubMedGoogle Scholar
• Chatterjee A, Frucht SJ. Tetrabenazine in the treatment of severe pediatric chorea. Mov Disord 2003;18:703-6
   PubMedGoogle Scholar
• Kenney C, Jankovic J. Tetrabenazine in the treatment of hyperkinetic movement disorders. Expert Rev Neurother 2006;6:7-17
   PubMedGoogle Scholar
• Kenney C, Hunter C, Mejia N, Is history of depression a contraindication to treatment with tetrabenazine? Clin Neuropharmacol 2006;29:259-64
   PubMed Web of Science ®Google Scholar
• Gimenez-Roldan S, Mateo D. Huntington disease: tetrabenazine compared to haloperidol in the reduction of involuntary movements. Neurologia 1989;4:282-7
   PubMedGoogle Scholar
• Kidd DW, McLellan DL. Self-poisoning with tetrabenazine. Br J Clin Pract 1972;26:179-80
   PubMedGoogle Scholar
• Stevens E, Roman A, Houa M, Severe hyperthermia during tetrabenazine therapy for tardive dyskinesia. Intensive Care Med 1998;24:369-71
   PubMedGoogle Scholar
• Burke RE, Fahn S, Mayeux R, Neuroleptic malignant syndrome caused by dopamine-depleting drugs in a patient with Huntington disease. Neurology 1981;31:1022-5
   PubMed Web of Science ®Google Scholar
• Mateo D, Munoz-Blanco JL, Gimenez-Roldan S. Neuroleptic malignant syndrome related to tetrabenazine introduction and haloperidol discontinuation in Huntington's disease. Clin Neuropharmacol 1992;15:63-8
   PubMed Web of Science ®Google Scholar
• Ossemann M, Sindic CJ, Laterre C. Tetrabenazine as a cause of neuroleptic malignant syndrome. Mov Disord 1996;11:95
   PubMed Web of Science ®Google Scholar
• Petzinger GM, Bressman SB. A case of tetrabenazine-induced neuroleptic malignant syndrome after prolonged treatment. Mov Disord 1997;12:246-8
   PubMedGoogle Scholar
• Huang CY, McLeod JG, Holland RT, Tetrabenazine in the treatment of Huntington's chorea. Med J Aust 1976;1:583-4
   PubMedGoogle Scholar
• Mestre T, Ferreira J, Coelho MM, Therapeutic interventions for symptomatic treatment in Huntington's disease. Cochrane Database Syst Rev 2009;CD006456
   PubMedGoogle Scholar
• Bonelli RM, Wenning GK. Pharmacological management of Huntington's disease: an evidence-based review. Curr Pharm Des 2006;12:2701-20
   PubMed Web of Science ®Google Scholar
• Brusa L, Orlacchio A, Moschella V, Treatment of the symptoms of Huntington's disease: preliminary results comparing aripiprazole and tetrabenazine. Mov Disord 2009;24:126-129
   PubMed Web of Science ®Google Scholar
• Rauchverger B, Isakov V, Jabarin M. Olanzapine-induced tardive dystonia successfully treated by tetrabenazine. J Neuropsychiatry Clin Neurosci 2007;19:484-5
   PubMed Web of Science ®Google Scholar
• Zaidi SH, Faruqui RA. Aripiprazole is associated with early onset of Tardive Dyskinesia like presentation in a patient with ABI and psychosis. Brain Inj 2008;22:99-102
   PubMed Web of Science ®Google Scholar
• Fasano A, Mazzone P, Piano C, GPi-DBS in Huntington's disease: results on motor function and cognition in a 72-year-old case. Mov Disord 2008;23:1289-92
   PubMed Web of Science ®Google Scholar
• Kenney C, Hunter C, Davidson A, Short-term effects of tetrabenazine on chorea associated with Huntington's disease. Mov Disord 2007;22:10-13
   PubMed Web of Science ®Google Scholar
• Watson MW, Skelton D, Jamali F. Treatment of tardive dyskinesia: preliminary report on use of tetrabenazine. Can J Psychiatry 1988;33:11-13
   PubMed Web of Science ®Google Scholar
• Shapiro AK, Shapiro AS, Bruun R. Gilles de la Tourette Syndrome. NY: Raven Press; 1978
   Google Scholar
• Kenney C, Hunter C, Mejia N, Tetrabenazine in the treatment of Tourette syndrome. J Pediatric Neurol 2007;5:9-13
   Google Scholar
• Jankovic J. Dystonia: medical therapy and botulinum toxin. Adv Neurol 2004;94:275-86
   PubMedGoogle Scholar